Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug;104(8):e244.
doi: 10.1097/TP.0000000000003229.

The Authors' Reply

Federica Invernizzi  1 , Massimo Iavarone
Affiliations
Comment

The Authors' Reply

Federica Invernizzi et al. Transplantation. 2020 Aug.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Mancuso A. Sorafenib for hepatocellular carcinoma recurrence after liver transplant. Transplantation. 2020In press
    1. Invernizzi F, Iavarone M, Zavaglia C, et al. Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation. Transplantation. 2019; 104:568–574
    1. Perricone G, Mancuso A, Belli LS, et al. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity? Eur J Gastroenterol Hepatol. 2014; 26:577–578
    1. Mancuso A, Mazzola A, Cabibbo G, et al. Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplant: a systematic review and meta-analysis. Dig Liver Dis. 2015; 47:324–330
    1. Iavarone M, Invernizzi F, Czauderna C, et al. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. Am J Transplant. 2019; 19:3176–3184

LinkOut - more resources